Testing effectiveness (Phase 2)Study completedNCT05906628What this trial is testingTopical Ruxolitinib Evaluation in Chronic Hand EczemaWho this might be right forHand Eczema Incyte Corporation 186
Large-scale testing (Phase 3)WithdrawnNCT05219864What this trial is testingTopical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1Who this might be right forHand Eczema Incyte Corporation
Early research (Phase 1)Study completedNCT02370706What this trial is testingStudy of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With MyelofibrosisWho this might be right forMyelofibrosis Novartis Pharmaceuticals 15
Testing effectiveness (Phase 2)Study completedNCT02953678What this trial is testingRuxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)Who this might be right forGraft-versus-host Disease (GVHD) Incyte Corporation 71
Testing effectiveness (Phase 2)Study completedNCT04916756What this trial is testingA Prospective Pilot Study to Explore Efficacy and Safety of Baricitinib in Active Primary Sjogren's Syndrome PatientsWho this might be right forSjogren's Syndrome Peking Union Medical College Hospital 11
Early research (Phase 1)Study completedNCT02531191What this trial is testingBioequivalence Evaluation of a New and Current Tablet of ASP015KWho this might be right forHealthy Volunteers Astellas Pharma Inc 40
Testing effectiveness (Phase 2)Study completedNCT04105010What this trial is testingAssessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)Who this might be right forRelapsed or Refractory Peripheral T Cell Lymphoma Dizal Pharmaceuticals 171
Large-scale testing (Phase 3)Study completedNCT04006457What this trial is testingLong-Term PF-06651600 for the Treatment of Alopecia AreataWho this might be right forAlopecia Areata Pfizer 1,057
Early research (Phase 1)Study completedNCT04769869What this trial is testingA Clinical Trial in Healthy Volunteers and Patients With Mild Asthma to Investigate a New Medicine (AZD4604) for the Treatment of AsthmaWho this might be right forAsthma AstraZeneca 110
Very early researchNot Yet RecruitingNCT06414681What this trial is testingCombination of Tagraxofusp with Pacritinib in Patients with Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy with the Approved JAK Inhibitors or in Which Therapy with the Approved JAK Inhibitors is Not Appropriate, Contraindicated or DeclinedWho this might be right forMyelofibrosis，MF University of Kansas Medical Center 20
Large-scale testing (Phase 3)Study completedNCT00934544What this trial is testingControlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II TrialWho this might be right forMyelofibrosis Novartis Pharmaceuticals 219
Post-approval studies (Phase 4)Looking for participantsNCT03976245What this trial is testingAdvanced Therapeutics in Rheumatoid Arthritis (RA)Who this might be right forRheumatoid Arthritis London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's 144
Large-scale testing (Phase 3)UnknownNCT05090410What this trial is testingEfficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to MethotrexateWho this might be right forRheumatoid ArthritisJAK InhibitorIL-6 Inhibitor+2 more Atsushi Kawakami 400
Testing effectiveness (Phase 2)Active Not RecruitingNCT06158113What this trial is testingEfficacy and Safety of Baricitinib in Oral Lichen Planus: a Proof-of-Concept StudyWho this might be right forLichen Planus, OralLichen Planus, MucosalOral Lichen Planus University of North Carolina, Chapel Hill 10
Large-scale testing (Phase 3)Study completedNCT01815424What this trial is testingA Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque PsoriasisWho this might be right forPsoriasis Pfizer 266
Testing effectiveness (Phase 2)Looking for participantsNCT06065046What this trial is testingBaricitinib for Moderate and Severe Traumatic Intracerebral Hemorrhage/ContusionsWho this might be right forTraumatic Brain Injury Tang-Du Hospital 100
Early research (Phase 1)Study completedNCT04004663What this trial is testingBioavailability Study of PF-06651600 Formulations in Healthy ParticipantsWho this might be right forHealthy Volunteers Pfizer 12
Testing effectiveness (Phase 2)Ended earlyNCT03395340What this trial is testingTopical Ruxolitinib for Cutaneous Chronic Graft Versus Host Disease (cGVHD)Who this might be right forGraft Versus Host DiseaseJNS KinaseTopical Administration National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) 1
Testing effectiveness (Phase 2)Looking for participantsNCT06715982What this trial is testingJAK Inhibitors for Solid Malignant Tumor Patients With Immune Checkpoint Inhibitors-related Dermatitis: A Open-lable, Single Arm, Phase IIa TrialWho this might be right forImmune Checkpoint Inhibitors (ICI)-Related Dermatitis Shixiu Wu 35
Testing effectiveness (Phase 2)WithdrawnNCT06619522What this trial is testingINCB57643 (BET Inhibitor) in Combination With Ruxolitinib in JAK Inhibitor-naïve Patients With MyelofibrosisWho this might be right forMyelofibrosis M.D. Anderson Cancer Center